Wird geladen...
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were e...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Informa Healthcare
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4133973/ https://ncbi.nlm.nih.gov/pubmed/24024472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.843090 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|